<DOC>
	<DOC>NCT00743405</DOC>
	<brief_summary>This is a First Time in Human Study to assess the safety, tolerability and pharmacokinetics of single doses of GSK1034702 in healthy subjects. It will be a single-blind, randomized, placebo-controlled, single oral dose, dose-rising, cross-over study in healthy male and female (of non-child bearing potential) subjects. Subjects will be randomized into cohorts of 10 subjects and cohorts will be recruited until the pre-defined safety or PK stopping limits are reached. Each subject will receive placebo and up to 4 doses of GSK1034702 in a randomized sequence on 5 separate study occasions.</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Healthy as determined by a responsible physician, based on a medical evaluation including own and familial medical history, physical examination, laboratory tests and cardiac monitoring. Male or female between 18 and 55 years of age. A female subject is eligible to participate if she is of nonchildbearing potential Body weight &gt; 50 kg and BMI within the range 19 29.9 kg/m2 (inclusive). Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. Capable of reading, comprehending and writing English at a sufficient level to complete studyrelated materials. Demonstrates no evidence of mental impairment. No comorbid Psychiatric Disorders as defined using the Mini International Neuropsychiatric Interview A positive prestudy drug/alcohol screen. A positive prestudy Hepatitis B , Hepatitis C or HIV. History of regular alcohol consumption. The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 halflives or twice the duration of the biological effect of the investigational product (whichever is longer). Exposure to more than four new chemical entities within 12 months prior to the first dosing day. Use of prescription or nonprescription drugs, including vitamins, herbal and dietary supplements . History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period. Pregnant females, females planning pregnancy or lactating females. Unwillingness or inability to follow the procedures outlined in the protocol. History of sensitivity to heparin or heparininduced thrombocytopenia. Subjects with a current or a history of psychiatric illness. Subjects with any history of suicidal attempts or behavior. Urinary cotinine levels indicative of smoking or history or regular use of tobacco or nicotinecontaining products. Consumption of red wine, seville oranges, grapefruit or grapefruit juice (and pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices) from 7 days prior to the first dose of study medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>M1 receptor agonist</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>GSK1034702</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>